I. Concepts -- 1. Pharmacologic control of specific gene expression -- 2. Modulation of the activity of cancer chemotherapeutic agents by dipyridamole -- II. New drugs and modifiers -- 3. Pharmacology and clinical investigation of SR-2508 (etanidazole) -- 4. Folate antimetabolites inhibitory to de novo purine synthesis -- 5. Taxol: A new agent active in melanoma and ovarian cancer -- 6. ICRF-187 (ADR-529) cardioprotection against anthracycline-induced cardiotoxicity: Clinical and preclinical studies -- 7. Uroprotection in patients receiving cyclophosphamide and ifosfamide -- III. Disease targets -- 8. The role of progesterone receptors in meningioma -- 9. Combined chemotherapy and radiotherapy in small-cell lung cancer -- Addendum to Chapter 2